On September 23, 2025, Illumina Inc. announced that it will partner with multiple global pharmaceutical companies to develop companion diagnostics (CDx) for the KRAS biomarker, using its TruSight™ Oncology Comprehensive genomic profiling test.
The KRAS oncogene is one of the most frequently mutated drivers of cancer, and the ability to identify KRAS alterations across tumor types enables clinicians to match patients with targeted therapies. By adding CDx claims for KRAS, Illumina expands its clinical portfolio and creates a new revenue source tied to the growing demand for precision oncology diagnostics.
This partnership leverages Illumina’s established TSO Comprehensive platform, positioning the company to capture a larger share of the CDx market and to support the development of targeted therapies in collaboration with its pharmaceutical partners.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.